Atricure (ATRC) Revenue by Segment

Shows how sales split across the company’s product lines and services, revealing which devices or consumables drive growth and profit. For Atricure, this highlights dependence on surgical ablation systems versus consumable disposables (and any emerging product lines), signals where adoption or pricing pressure could affect margins, and points to which segments offer the most upside if clinical adoption or reimbursement improves.

Atricure is transitioning from a MIS-dependent company to one driven by pain management, appendage management and open ablation—MIS revenue has steadily eroded while pain and appendage have accelerated, fueled by cryoSPHERE MAX, new clips and EnCompass adoption. That shift explains the stronger cash generation and raised adjusted‑EBITDA outlook, but investors should watch near‑term risks: international reimbursement softness, a manufacturing transition, anticipated IPR&D charges and new competitive entrants in appendage could compress GAAP margins and accentuate expected Q3 seasonality.